Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
Objectives Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post...
Main Authors: | Renaud Felten, Jacques-Eric Gottenberg, Lionel Spielmann, Pierre-Marie Duret, Laurent Messer, Corine Gaillez, Weibin Bao, Laura Widawski |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-10-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/4/e003428.full |
Similar Items
-
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2022) -
Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
by: Laure Gossec, et al.
Published: (2022-07-01) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01) -
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
by: Baraliakos, X, et al.
Published: (2020) -
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
by: Laura C. Coates, et al.
Published: (2019-12-01)